Citi initiated coverage of Agilon Health with a Neutral rating and $6 price target. The analyst says Agilon is in a “precarious position,” as it currently has very little flexibility in its model since it is 100% dedicated to full capitation in Medicare Advantage. To become profitable, the market environment will have to materially improve, which is unlikely, or Agilon must renegotiate its contracts, the analyst tells investors in a research note. Citi does not think Agilon has the negotiating power to materially improve its contracts.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Insurer stocks tumble as Medicare Advantage rates disappoint
- CMS finalizes payment update for 2025 Medicare Advantage, sees payments up 3.7%
- Agilon Health falls -9.9%
- Contact Levi & Korsinsky LLP by May 20, 2024 Deadline to Join Class Action Against agilon health, inc.(AGL)
- Barclays starts health care facilities, managed care group with Neutral view